Evidence map›Paper›PMID 37032720›Full record

ArticleNon-coding RNA research2023

Telomerase RNA component lncRNA as potential diagnostic biomarker promotes CRC cellular migration and apoptosis evasion via modulation of β-catenin protein level.

Mohamed Bakr, Mai A Abd-Elmawla, Hanan Elimam, Hebatallah Gamal El-Din, Amal Fawzy, Ahmed I Abulsoud, Sherine M Rizk

Open access · goldAbstract read
In one paragraph

Article in Non-coding RNA research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 67 citations in OpenAlex.

  1. SerumInternational journal of molecular sciences · 2026
    Article
  2. Molecular insight into the therapeutic potential of miR-34a in retinoblastoma.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mohamed BakrDepartment of Biochemistry, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt.
Mai A Abd-ElmawlaDepartment of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Hanan ElimamDepartment of Biochemistry, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt.
Hebatallah Gamal El-DinDepartment of Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Amal FawzyDepartment of Clinical and Chemical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.
Ahmed I AbulsoudDepartment of Biochemistry, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Sherine M RizkDepartment of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Cairo University · EGAl-Azhar University · EGSinai University · EGUniversity of Sadat City · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Long non-coding RNA (LncRNA) telomerase RNA component (TERC) has telomerase-dependent and independent activity in numerous cancer types. The present study purposes to demonstrate the role of lncRNA TERC as a diagnostic serum biomarker in colorectal cancer (CRC) patients and the molecular mechanism of lncRNA TERC in inducing tumor in CRC cell lines. Materials and methods: PCR array was performed to examine lncRNAs dysregulated in CRC. LncRNA TERC expression level was evaluated in 70 CRC patients and 35 control subjects using RT-qPCR. Then transfection was performed to build down-expression models of lncRNA TERC. ROC curve analysis was applied to assess the diagnostic value of serum LncRNA CRC. In addition, RT-qPCR was used to detect expression level of lncRNA TERC and β-catenin mRNA. Moreover, ELISA and Western blot were used to detect the level of β-catenin protein in sera of CRC patients and cell lines. The biological functions such as cell growth and migration of CRC cells were assessed using a wound healing assay. Cell cycle analysis and apoptosis analysis were performed using flow cytometry. Results: The lncRNA TERC is overexpressed in the sera of CRC patients with high diagnostic and stage discrimination accuracy. Furthermore, lncRNA TERC expression was upregulated in CRC cell lines and lncRNA TERC silencing induced cell arrest and apoptosis and inhibited cell migration. Furthermore, inhibition of lncRNA TERC reduces β-catenin protein levels. Conclusion: The lncRNA TERC could be considered as an early stages CRC diagnostic biomarker with a good ability to discriminate between CRC stages. lncRNA TERC induces CRC by promoting cell migration and evading apoptosis by elevating the level of β-catenin protein.

Indexed as

Apoptosis evadingColorectal cancerDiagnostic biomarkersLncRNAsTERCβ-catenin protein

Identifiers

PMID37032720
PMCPMC10074408
OpenAlexW4328053360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.